{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:05:16Z","timestamp":1794927916810,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8110","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Engineered T cells, reprogrammed to express chimeric antigen receptors (CAR) or T cell receptors (TCR), have transformed cancer treatment and are being explored as\u00a0therapeutics for autoimmune and infectious diseases. Enhancing T cell function through genome editing, either by disrupting endogenous genes or precisely inserting DNA payloads, has shown considerable promise\n                    <jats:sup>1<\/jats:sup>\n                    . However, the ex vivo manufacturing process is lengthy and costly, limiting accessibility of these therapies. In vivo generation of CAR\u00a0T cells could overcome these barriers, but current methods rely either on transient expression with limited durability, or on\u00a0random integration of DNA payloads that lack specificity. Here we demonstrate that stable and cell-specific transgene expression can be achieved through in vivo site-specific integration of large DNA payloads. We developed a two-vector system to deliver CRISPR\u2013Cas9 ribonucleoproteins and a DNA donor template, using enveloped delivery vehicles and adeno-associated viruses, respectively. We optimized both vectors for T cell-specific delivery and gene-targeting efficiency. By integrating a CAR transgene into a T cell-specific locus, we generate therapeutic levels of CAR\u00a0T cells in vivo in humanized mouse models of B cell aplasia, and\u00a0haematological and solid malignancies. These findings offer a pathway to more efficient, precise and widely accessible T cell therapies.\n                  <\/jats:p>","DOI":"10.1038\/s41586-026-10235-x","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:01:30Z","timestamp":1773849690000},"page":"712-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["In vivo site-specific engineering to reprogram T cells"],"prefix":"10.1038","volume":"652","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9982-1305","authenticated-orcid":false,"given":"William A.","family":"Nyberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-619X","authenticated-orcid":false,"given":"Pierre-Louis","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-2303","authenticated-orcid":false,"given":"Wayne","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-2077","authenticated-orcid":false,"given":"Charlotte H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6734-6180","authenticated-orcid":false,"given":"Allison","family":"Rothrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina M.","family":"Borgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2920-2218","authenticated-orcid":false,"given":"Gabriella R.","family":"Kimmerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Allain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-1757","authenticated-orcid":false,"given":"Jennifer R.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Stickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safwaan H.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niran","family":"Almudhfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Novick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasaman","family":"Mortazavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"AbdElwakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis R.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-1548","authenticated-orcid":false,"given":"Simon N.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2665-0434","authenticated-orcid":false,"given":"Hyuncheol","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1294-9686","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-537X","authenticated-orcid":false,"given":"Ansuman T.","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-7148","authenticated-orcid":false,"given":"Julia","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Rutishauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8198-5010","authenticated-orcid":false,"given":"M. Kyle","family":"Cromer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-7954","authenticated-orcid":false,"given":"Kole T.","family":"Roybal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-5507","authenticated-orcid":false,"given":"Stacie E.","family":"Dodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Doudna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5563-4877","authenticated-orcid":false,"given":"Aravind","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-1190","authenticated-orcid":false,"given":"Justin","family":"Eyquem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"10235_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"10235_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang, X. & Riviere, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolyt. 3, 16015 (2016).","journal-title":"Mol. Ther. Oncolyt."},{"key":"10235_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/MB:15:2:133","volume":"15","author":"I Riviere","year":"2000","unstructured":"Riviere, I., Gallardo, H. F., Hagani, A. B. & Sadelain, M. Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Mol. Biotechnol. 15, 133\u2013142 (2000).","journal-title":"Mol. Biotechnol."},{"key":"10235_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","volume":"186","author":"WA Nyberg","year":"2023","unstructured":"Nyberg, W. A. et al. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell 186, 446\u2013460 (2023).","journal-title":"Cell"},{"key":"10235_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.jcyt.2023.03.011","volume":"25","author":"E Lau","year":"2023","unstructured":"Lau, E. et al. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy 25, 750\u2013762 (2023).","journal-title":"Cytotherapy"},{"key":"10235_CR6","doi-asserted-by":"crossref","unstructured":"Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl. Med. 9, eaaj2013 (2017).","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"10235_CR7","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885\u20131894 (2020).","journal-title":"Lancet"},{"key":"10235_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","volume":"45","author":"L Short","year":"2024","unstructured":"Short, L., Holt, R. A., Cullis, P. R. & Evgin, L. Direct in vivo CAR T cell engineering. Trends Pharmacol. Sci. 45, 406\u2013418 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"10235_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","volume":"117","author":"CS Hinrichs","year":"2011","unstructured":"Hinrichs, C. S. et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808\u2013814 (2011).","journal-title":"Blood"},{"key":"10235_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"10235_CR11","doi-asserted-by":"crossref","unstructured":"Cael, B. et al. Umbilical cord blood as a source of less differentiated T cells to produce CD123 CAR-T cells. Cancers 14, 3168 (2022).","DOI":"10.3390\/cancers14133168"},{"key":"10235_CR12","doi-asserted-by":"crossref","unstructured":"Pfeiffer, A. et al. In vivo generation of human CD19-CAR T cells results in B-cell depletion and signs of cytokine release syndrome. EMBO Mol. Med. 10, EMMM201809158 (2018).","DOI":"10.15252\/emmm.201809158"},{"key":"10235_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813\u2013820 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"10235_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"10235_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020).","journal-title":"Nat. Commun."},{"key":"10235_CR16","doi-asserted-by":"crossref","unstructured":"Michels, K. R. et al. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering. J. Immunother. Cancer 11, e006292 (2023).","DOI":"10.1136\/jitc-2022-006292"},{"key":"10235_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1182\/blood.2024024523","volume":"144","author":"CJ Nicolai","year":"2024","unstructured":"Nicolai, C. J. et al. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand. Blood 144, 977\u2013987 (2024).","journal-title":"Blood"},{"key":"10235_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter, T. L. et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science 388, 1311\u20131317 (2025).","journal-title":"Science"},{"key":"10235_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","volume":"406","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma. Lancet 406, 228\u2013231 (2025).","journal-title":"Lancet"},{"key":"10235_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","volume":"22","author":"C Booth","year":"2016","unstructured":"Booth, C., Gaspar, H. B. & Thrasher, A. J. Treating Immunodeficiency through HSC gene therapy. Trends Mol. Med. 22, 317\u2013327 (2016).","journal-title":"Trends Mol. Med."},{"key":"10235_CR21","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499\u20131503 (2018).","journal-title":"Nat. Med."},{"key":"10235_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2021.09.014","volume":"23","author":"A Michels","year":"2021","unstructured":"Michels, A. et al. Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8. Mol. Ther. Methods Clin. Dev. 23, 334\u2013347 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10235_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.omtm.2018.10.006","volume":"12","author":"AM Frank","year":"2019","unstructured":"Frank, A. M. & Buchholz, C. J. Surface-engineered lentiviral vectors for selective gene transfer into subtypes of lymphocytes. Mol. Ther. Methods Clin. Dev. 12, 19\u201331 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10235_CR24","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1002\/jgm.494","volume":"6","author":"E Verhoeyen","year":"2004","unstructured":"Verhoeyen, E. & Cosset, F. L. Surface-engineering of lentiviral vectors. J. Gene Med. 6, S83\u2013S94 (2004).","journal-title":"J. Gene Med."},{"key":"10235_CR25","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 3, 2317\u20132322 (2019).","journal-title":"Blood Adv."},{"key":"10235_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"10235_CR27","doi-asserted-by":"crossref","unstructured":"Hamilton, J. R. et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. 42, 1684\u20131692 (2024).","DOI":"10.1038\/s41587-023-02085-z"},{"key":"10235_CR28","doi-asserted-by":"publisher","first-page":"307ra156","DOI":"10.1126\/scitranslmed.aac5530","volume":"7","author":"BD Sather","year":"2015","unstructured":"Sather, B. D. et al. Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156 (2015).","journal-title":"Sci. Transl. Med."},{"key":"10235_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","volume":"28","author":"EJ Pomeroy","year":"2020","unstructured":"Pomeroy, E. J. et al. A genetically engineered primary human natural killer cell platform for cancer immunotherapy. Mol. Ther. 28, 52\u201363 (2020).","journal-title":"Mol. Ther."},{"key":"10235_CR30","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","volume":"33","author":"J Wang","year":"2015","unstructured":"Wang, J. et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256\u20131263 (2015).","journal-title":"Nat. Biotechnol."},{"key":"10235_CR31","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","volume":"90","author":"JC Burns","year":"1993","unstructured":"Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl Acad. Sci. USA 90, 8033\u20138037 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10235_CR32","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/nar\/gkaa1251","volume":"49","author":"YW Fu","year":"2021","unstructured":"Fu, Y. W. et al. Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res. 49, 969\u2013985 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10235_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"10235_CR34","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1093\/nar\/gkh703","volume":"32","author":"N Saleh-Gohari","year":"2004","unstructured":"Saleh-Gohari, N. & Helleday, T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res. 32, 3683\u20133688 (2004).","journal-title":"Nucleic Acids Res."},{"key":"10235_CR35","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1093\/nar\/gkv1121","volume":"44","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Res. 44, e30 (2016).","journal-title":"Nucleic Acids Res."},{"key":"10235_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101126","volume":"31","author":"Y Pan","year":"2023","unstructured":"Pan, Y. et al. A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies. Mol. Ther. Methods Clin. Dev. 31, 101126 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10235_CR37","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971 (2018).","journal-title":"Cell"},{"key":"10235_CR38","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature16465","volume":"530","author":"S Pillay","year":"2016","unstructured":"Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530, 108\u2013112 (2016).","journal-title":"Nature"},{"key":"10235_CR39","doi-asserted-by":"publisher","first-page":"9093","DOI":"10.1128\/JVI.00895-06","volume":"80","author":"Z Wu","year":"2006","unstructured":"Wu, Z., Miller, E., Agbandje-McKenna, M. & Samulski, R. J. \u03b12,3 and \u03b12,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80, 9093\u20139103 (2006).","journal-title":"J. Virol."},{"key":"10235_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03432-4","volume":"9","author":"J Nikolic","year":"2018","unstructured":"Nikolic, J. et al. Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein. Nat. Commun. 9, 1029 (2018).","journal-title":"Nat. Commun."},{"key":"10235_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","volume":"38","author":"DN Nguyen","year":"2020","unstructured":"Nguyen, D. N. et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat. Biotechnol. 38, 44\u201349 (2020).","journal-title":"Nat. Biotechnol."},{"key":"10235_CR42","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"10235_CR43","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good, Z. et al. Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860\u20131871 (2022).","journal-title":"Nat. Med."},{"key":"10235_CR44","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin. Cancer Res. 27, 1227\u20131235 (2021).","journal-title":"Clin. Cancer Res."},{"key":"10235_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.omtm.2021.02.013","volume":"21","author":"N Cordes","year":"2021","unstructured":"Cordes, N. et al. Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. Mol. Ther. Methods Clin. Dev. 21, 42\u201353 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10235_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07845-z","volume":"10","author":"PE Mangeot","year":"2019","unstructured":"Mangeot, P. E. et al. Genome editing in primary cells and in vivo using viral-derived nanoblades loaded with Cas9-sgRNA ribonucleoproteins. Nat. Commun. 10, 45 (2019).","journal-title":"Nat. Commun."},{"key":"10235_CR47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250\u2013265.e16 (2022).","journal-title":"Cell"},{"key":"10235_CR48","doi-asserted-by":"crossref","unstructured":"An, M. et al. Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat. Biotechnol. 42, 1526\u20131537 (2024).","DOI":"10.1038\/s41587-023-02078-y"},{"key":"10235_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","volume":"21","author":"S Boutin","year":"2010","unstructured":"Boutin, S. et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21, 704\u2013712 (2010).","journal-title":"Hum. Gene Ther."},{"key":"10235_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342\u2013347 (2006).","journal-title":"Nat. Med."},{"key":"10235_CR51","doi-asserted-by":"crossref","unstructured":"Uhlen, M. et al. A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Science 366, eaax9198 (2019).","DOI":"10.1126\/science.aax9198"},{"key":"10235_CR52","doi-asserted-by":"crossref","unstructured":"Karlsson, M. et al. A single-cell type transcriptomics map of human tissues. Sci. Adv. 7, eabh2169 (2021).","DOI":"10.1126\/sciadv.abh2169"},{"key":"10235_CR53","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","volume":"32","author":"MB Demircan","year":"2024","unstructured":"Demircan, M. B. et al. T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8. Mol Ther 32, 3470\u20133484 (2024).","journal-title":"Mol Ther"},{"key":"10235_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122399","volume":"303","author":"SA Theuerkauf","year":"2023","unstructured":"Theuerkauf, S. A. et al. AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery. Biomaterials 303, 122399 (2023).","journal-title":"Biomaterials"},{"key":"10235_CR55","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall, M. T. N. et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol. 41, 500\u2013512 (2023).","journal-title":"Nat. Biotechnol."},{"key":"10235_CR56","doi-asserted-by":"crossref","unstructured":"Pandey, S. et al. Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat. Biomed. Eng. 9, 22\u201339 (2024).","DOI":"10.1038\/s41551-024-01227-1"},{"key":"10235_CR57","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41587-022-01574-x","volume":"41","author":"CJ Tou","year":"2023","unstructured":"Tou, C. J., Orr, B. & Kleinstiver, B. P. Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases. Nat. Biotechnol. 41, 968\u2013979 (2023).","journal-title":"Nat. Biotechnol."},{"key":"10235_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","volume":"58","author":"WA Nyberg","year":"2025","unstructured":"Nyberg, W. A. et al. In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313. Immunity 58, 499\u2013512 (2025).","journal-title":"Immunity"},{"key":"10235_CR59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2413519121","volume":"122","author":"W Ngo","year":"2025","unstructured":"Ngo, W. et al. Mechanism-guided engineering of a minimal biological particle for genome editing. Proc. Natl Acad. Sci. USA 122, e2413519121 (2025).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10235_CR60","doi-asserted-by":"crossref","unstructured":"Huang, R. S., Lai, M. C., Shih, H. A. & Lin, S. A robust platform for expansion and genome editing of primary human natural killer cells. J. Exp. Med. 218, e20201529 (2021).","DOI":"10.1084\/jem.20201529"},{"key":"10235_CR61","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41591-021-01284-y","volume":"27","author":"MK Cromer","year":"2021","unstructured":"Cromer, M. K. et al. Gene replacement of alpha-globin with beta-globin restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells. Nat. Med. 27, 677\u2013687 (2021).","journal-title":"Nat. Med."},{"key":"10235_CR62","doi-asserted-by":"publisher","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","volume":"114","author":"LV Tse","year":"2017","unstructured":"Tse, L. V. et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc. Natl Acad. Sci. USA 114, E4812\u2013E4821 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10235_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00587-21","volume":"95","author":"LP Havlik","year":"2021","unstructured":"Havlik, L. P. et al. Receptor switching in newly evolved adeno-associated viruses. J. Virol. 95, e0058721 (2021).","journal-title":"J. Virol."},{"key":"10235_CR64","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.cell.2018.11.044","volume":"176","author":"J Henriksson","year":"2019","unstructured":"Henriksson, J. et al. Genome-wide CRISPR screens in T helper cells reveal pervasive crosstalk between activation and differentiation. Cell 176, 882\u2013896 (2019).","journal-title":"Cell"},{"key":"10235_CR65","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/s41588-022-01106-y","volume":"54","author":"JW Freimer","year":"2022","unstructured":"Freimer, J. W. et al. Systematic discovery and perturbation of regulatory genes in human T cells reveals the architecture of immune networks. Nat. Genet. 54, 1133\u20131144 (2022).","journal-title":"Nat. Genet."},{"key":"10235_CR66","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1002\/cpz1.222","volume":"1","author":"L Ferrer-Font","year":"2021","unstructured":"Ferrer-Font, L. et al. Panel optimization for high-dimensional immunophenotyping assays using full-spectrum flow cytometry. Curr. Protoc. 1, e222 (2021).","journal-title":"Curr. Protoc."},{"key":"10235_CR67","doi-asserted-by":"publisher","unstructured":"Nyberg, W. A. et al. Code for \u2018In vivo site-specific engineering to reprogram T cells\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.17372997 (2026).","DOI":"10.5281\/zenodo.17372997"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10235-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:02:57Z","timestamp":1776322977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":67,"journal-issue":{"issue":"8110","published-print":{"date-parts":[[2026,4,16]]}},"alternative-id":["10235"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10235-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"24 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.A.N., J.E., J.A., A.A., W.N., J.R.H. and J.A.D. are listed as inventors on multiple patent applications filed on the subject matters related to this study. J.E. is a compensated co-founder at Mnemo Therapeutics and Azalea Therapeutics and a compensated scientific advisor to Enterome, Treefrog Therapeutics and Brink Therapeutics. J.E. owns stocks in Azalea Therapeutics, Mnemo Therapeutics, Brink Therapeutics and Cytovia Therapeutics. The J.E. laboratory has received research support from Mnemo Therapeutics and Takeda Pharmaceutical Company. M.K.C. is a shareholder of Kamau Therapeutics. S.E.D. is a shareholder of Site Tx. J.R.H. is a cofounder of Azalea Therapeutics. J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Isomorphic Labs, BEVC Management, Evercrisp, Caribou Biosciences, Scribe Therapeutics, Mammoth Biosciences, The Column Group and Inari; an advisor for Aditum Bio; and a chief science advisor to Sixth Street, a director at Johnson & Johnson, Altos and Tempus, and has a research project sponsored by Apple Tree Partners.\u00a0A.A. is a co-founder at Torque Bio, Lucidigm Therapeutics and the ATG Project Inc. He is a compensated scientific advisor for Coave Therapeutics, nChroma Bio, Atsena Therapeutics, Solid Biosciences and Sphere Gene Therapies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}